Nynke S. van Den Berg

Nynke S. van Den Berg

Auto-generated profile, based on publicly available information

Nynke S. van Den Berg

Department of Research, Intuitive Surgical Inc., Sunnyvale, California

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
GLGuolan Lu
Guolan Lu
NNNaoki Nishio
Naoki Nishio
NBNynke S. van Den Berg
Nynke S. van Den Berg
BMBrock A. Martin
Brock A. Martin
SFShayan Fakurnejad
Shayan Fakurnejad
EREben L. Rosenthal
Eben L. Rosenthal
Poor tissue penetration remains a major challenge for antibody-based therapeutics of solid tumors, but proper dosing can improve the tissue penetration and thus therapeutic efficacy of these biologics. Due to dose-limiting toxicity of the small molecule payload, antibody-drug conjugates (ADCs) are administered at a much lower dose than their parent antibodies, which further reduces tissue penetration. We conducted an early-phase clinical trial (NCT02415881) and previously reported the safety of an antibody-dye conjugate (panitumumab-IRDye800CW) as primary outcome. Here, we report a retrospective exploratory analysis of the trial to evaluate whether co-administration of an unconjugated antibody could improve the intratumoral distribution of the antibody-dye conjugate in patients. By measuring the multiscale distribution of the antibody-dye conjugate, this study demonstrates improved microscopic antibody distribution without increasing uptake (toxicity) in healthy tissue when co-administered with the parent antibody, supporting further clinical investigation of the co-administration dosing strategy to improve the tumor penetration of ADCs.

6 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NNNaoki Nishio
Naoki Nishio
NBNynke S. van Den Berg
Nynke S. van Den Berg
SKStan van Keulen
Stan van Keulen
BMBrock A. Martin
Brock A. Martin
SFShayan Fakurnejad
Shayan Fakurnejad
EREben L. Rosenthal
Eben L. Rosenthal
Identification of lymph node (LN) metastasis is essential for staging of solid tumors, and as a result, surgeons focus on harvesting significant numbers of LNs during ablative procedures for pathological evaluation. Isolating those LNs most likely to harbor metastatic disease can allow for a more rigorous evaluation of fewer LNs. Here we evaluate the impact of a systemically injected, near-infrared fluorescently-labeled, tumor-targeting contrast agent, panitumumab-IRDye800CW, to facilitate the identification of metastatic LNs in the ex vivo setting for head and neck cancer patients. Molecular imaging demonstrates a significantly higher mean fluorescence signal in metastatic LNs compared to benign LNs in head and neck cancer patients undergoing an elective neck dissection. Molecular imaging to preselect at-risk LNs may thus allow a more rigorous examination of LNs and subsequently lead to improved prognostication than regular neck dissection.

14 June 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BKBernhard Kiss
Bernhard Kiss
NBNynke S. van Den Berg
Nynke S. van Den Berg
RERobert Ertsey
Robert Ertsey
KMKelly McKenna
Kelly McKenna
KMKathleen E. Mach
Kathleen E. Mach
JLJoseph C. Liao
Joseph C. Liao
Purpose: Near-infrared photoimmunotherapy (NIR-PIT) is a localized molecular cancer therapy combining a photosensitizer-conjugated mAb and light energy. CD47 is an innate immune checkpoint widely expressed on bladder cancer cells, but absent from luminal normal urothelium. Targeting CD47 for NIR-PIT has the potential to selectively induce cancer cell death and minimize damage to normal urothelium. Experimental Design: The cytotoxic effect of NIR-PIT with anti-CD47-IR700 was investigated in human bladder cancer cell lines and primary human bladder cancer cells derived from fresh surgical samples. Phagocytosis assays were performed to evaluate macrophage activity after NIR-PIT. Anti-CD47-IR700 was administered to murine xenograft tumor models of human bladder cancer for in vivo molecular imaging and NIR-PIT. Results: Cytotoxicity in cell lines and primary bladder cancer cells significantly increased in a light-dose–dependent manner with CD47-targeted NIR-PIT. Phagocytosis of cancer cells significantly increased with NIR-PIT compared with antibody alone (P = 0.0002). In vivo fluorescence intensity of anti-CD47-IR700 in tumors reached a peak 24-hour postinjection and was detectable for at least 14 days. After a single round of CD47-targeted NIR-PIT, treated animals showed significantly slower tumor growth compared with controls (P < 0.0001). Repeated CD47-targeted NIR-PIT treatment further slowed tumor growth (P = 0.0104) and improved survival compared with controls. Conclusions: CD47-targeted NIR-PIT increased direct cancer cell death and phagocytosis resulting in inhibited tumor growth and improved survival in a murine xenograft model of human bladder cancer.

1 August 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SKStan van Keulen
Stan van Keulen
NNNaoki Nishio
Naoki Nishio
ABAndrew Birkeland
Andrew Birkeland
SFShayan Fakurnejad
Shayan Fakurnejad
BMBrock Martin
Brock Martin
EREben Rosenthal
Eben Rosenthal
Purpose: Despite major advancements in surgical oncology, the positive margin rate for primary head and neck cancer resection remains around 15%–30%. In particular, the deep surface margin is the most challenging to adequately assess. Inadequate margins are directly correlated to poor survival, and as such, mitigation of these rates is critical to improve patient outcomes. We have developed an ex vivo imaging strategy that utilizes fluorescence intensity peaks (relative to background signal) of an injected anti-EGFR antibody conjugated to a fluorescent probe to locate potential close or positive margins on the deep surface of the resected tumor specimen. Experimental Design: Twelve patients with head and neck cancer scheduled for surgery received systemic administration of a tumor-specific contrast-agent (panitumumab-IRDye800CW). After surgical resection, the tumor specimen was imaged using a fluorescence imager. The three highest fluorescence intensity-peaks on the deep surface of the specimen were isolated and correlated to histology to determine the margin distance at these regions. Results: Relative fluorescence peak intensities identified the closest margin on the deep surface of the specimen within 2.5 minutes. The highest intensity peak consistently (100%) detected the closest margin to the tumor. The difference in tumor margin distance between the first and second highest fluorescence intensity peak averaged 2.1 ± 1.4 mm. The tumor-margin difference between the second and third highest peak averaged 1.6 ± 0.6 mm. Conclusions: Fluorescence intensity peaks can identify the region on the specimen where tumor is closest to specimen9s edge on the deep surface. This technique could have broad applications in obtaining adequate margins in oncological surgery.

24 January 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GLGuolan Lu
Guolan Lu
SFShayan Fakurnejad
Shayan Fakurnejad
BMBrock A. Martin
Brock A. Martin
NBNynke S. van Den Berg
Nynke S. van Den Berg
SKStan van Keulen
Stan van Keulen
EREben L. Rosenthal
Eben L. Rosenthal
Purpose: The efficacy of antibody-based therapeutics depends on successful drug delivery into solid tumors; therefore, there is a clinical need to measure intratumoral antibody distribution. This study aims to develop and validate an imaging and computation platform to directly quantify and predict antibody delivery into human head and neck cancers in a clinical study. Experimental Design: Twenty-four patients received systemic infusion of a near-infrared fluorescence-labeled therapeutic antibody followed by surgical tumor resection. A computational platform was developed to quantify the extent of heterogeneity of intratumoral antibody distribution. Both univariate and multivariate regression analyses were used to select the most predictive tumor biological factors for antibody delivery. Quantitative image features from the pretreatment MRI were extracted and correlated with fluorescence imaging of antibody delivery. Results: This study not only confirmed heterogeneous intratumoral antibody distribution in-line with many preclinical reports, but also quantified the extent of interpatient, intertumor, and intratumor heterogeneity of antibody delivery. This study demonstrated the strong predictive value of tumor size for intratumoral antibody accumulation and its significant impact on antibody distribution in both primary tumor and lymph node metastasis. Furthermore, this study established the feasibility of using contrast-enhanced MRI to predict antibody delivery. Conclusions: This study provides a clinically translatable platform to measure antibody delivery into solid tumors and yields valuable insight into clinically relevant antibody tumor penetration, with implications in the selection of patients amenable to antibody therapy and the design of more effective dosing strategies.

29 September 2016 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
GKGijs H KleinJan
Gijs H KleinJan
DHDaan Hellingman
Daan Hellingman
NBNynke S. van Den Berg
Nynke S. van Den Berg
MOMatthias N. van Oosterom
Matthias N. van Oosterom
KHKees Hendricksen
Kees Hendricksen
Fijs Van LeeuwenFijs Van Leeuwen
Fijs Van Leeuwen
Introduction: The clinically applied hybrid tracer indocyanine green (ICG)-99mTc-nanocolloid enables combined radio- and fluorescence image guidance during sentinel node (SN) biopsy procedures. In order to provide optimal surgical guidance this tracer requires the presence of both gamma and fluorescence modalities in the operating room. We reasoned that combination and/or integration of these modalities could further evolve the hybrid surgical guidance concept. To study this potential we clinically applied two set-ups that included the combination of gamma detection modalities and an open surgery fluorescence camera. Methods: To attach the fluorescence camera (VITOM) to either 1) a gamma-ray detection probe (GP; VITOM-GP) or 2) a portable gamma camera (GC) (VITOM-GC), clip-on brackets were designed and 3D-printed in sterilizable RC31. Both combined modalities were evaluated in respectively five and six patients with penile cancer during a SN biopsy procedure using ICG-99mTc-nanocolloid. Intraoperatively, radio- and fluorescence guided SN detection rates were scored at working distances of 0, 10, 20, and 30 cm for both combinations. Results: Using the VITOM-GP combination 9 SNs were evaluated. Gamma tracing rates were shown to be 100, 88.9, 55.6 and 55.6 % at a respective working distance of 0, 10, 20 and 30 cm. Detection rates for the fluorescence imaging-based detection were found to be 100, 77.8 and 77.8 %, at respective working distances of 10, 20, and 30 cm. Using the VITOM-GC set-up, all 10 intraoperatively evaluated SNs could be visualized with the gamma camera independent of the working distance. Fluorescence detection rates were 90, 80 and 80% at 10, 20 and 30cm working distance. The integrated detection modalities were shown to work synergistically; overall the GC was most valuable for rough localization (10-30 cm range) of the SNs, the GP for providing convenient real-time acoustic feedback, while fluorescence guidance allowed detailed real-time SN visualization. Conclusion: Our findings suggest that full integration of a fluorescence camera with gamma detector (GP or GC) can be of value when a hybrid, radioactive and fluorescent, tracer is used.